GIA
HZNP

Gateway Investment Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Gateway Investment Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,281
Closed -$727K – 523
2023
Q3 		$727K Hold
6,281
– – 0.01% 344
2023
Q2 		$646K Hold
6,281
– – 0.01% 356
2023
Q1 		$686K Buy
6,281
+2,666
+74% +$295K 0.01% 363
2022
Q4 		$411K Buy
+3,615
New +$300K 0.01% 428

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Gateway Investment Advisers's HZNP Position: Q4 2023 in Review

Gateway Investment Advisers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 6,281 shares — an estimated $727K sold.

Gateway Investment Advisers first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $727K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Gateway Investment Advisers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Gateway Investment Advisers sold 6,281 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $727K.
  • Gateway Investment Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Gateway Investment Advisers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $727K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Gateway Investment Advisers's 13F filing for Q4 2023, filed 10 Jan 2024.